Cardio Diagnostics Holdings (NASDAQ: CDIO), an artificial intelligence (“AI”)-driven precision cardiovascular medicine company, announced the release of a whitepaper examining diagnostic challenges associated with non-obstructive coronary artery disease (“NOCAD”), a condition in which patients experience symptoms of coronary disease without significant blockages in major coronary arteries. The report focuses on limitations of invasive coronary angiography, which evaluates coronary anatomy rather than function, and highlights ischemia with no obstructive coronary arteries (“INOCA”), a condition affecting an estimated 3 million to 4 million Americans. It also outlines clinical approaches to identifying patients earlier, including the potential role of epigenetics-based testing in primary care.
The whitepaper examines NOCAD subgroups, diagnostic pathways and opportunities to improve detection of coronary disease that may not be identified through conventional angiography. Cardio Diagnostics also highlighted its ongoing efforts to build clinical evidence supporting PrecisionCHD, its AI- and epigenetics-based blood test designed to aid in diagnosing coronary heart disease, including its potential application in identifying patients with INOCA whose symptoms remain unexplained by traditional testing.
To view the full press release, visit https://ibn.fm/N5RnS
About Cardio Diagnostics
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease.
NOTE TO INVESTORS: The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN